Phase 1: mRNA therapy to fight metastases in solid tumors

[Maxone73]

TTX-MC138, an RNA-based therapeutic targeting microRNA-10b, implicated in metastatic cancers is currently in Phase 1 clinical trial.

The trial has progressed to its fourth cohort, administering a dose approximately 50% higher than the previous cohort, with no significant safety issues or dose-limiting toxicities reported.

Of the ten patients treated across the four cohorts, seven continue without disease progression. Preliminary pharmacokinetic and pharmacodynamic data align with preclinical and Phase 0 findings, indicating predictable behavior in humans. The Safety Review Committee has also approved additional enrollment in cohort three to further assess safety

prostatewarriors.com/2025/0...